BRAF and melanoma: Of the total, 106 (89.1%) melanomas were classified into the four major groups: 48/119 (40.3%) “BRAF+”, 15/119 (12.6%) “RAS+”, 10/119 (8.4%) “NF1+”, and 33/119 (27.7%) “3wt”; however, 13 (10.9%) patients, due to mutations in overlapping genes, eluded classification: 3/119 (2.5%) melanomas showed both a BRAF and RAS mutation, 9/119 (7.6%) showed both a BRAF and NF1 mutation, and 1/119 (0.8%) showed a mutation in both RAS and NF1 (Table 2).